Trastuzumab treatment is associated with ferroptosis-related alterations in HER2-positive breast cancer organoids
Cancer Chemotherapy and Pharmacology · 2026
DOI: 10.1007/s00280-026-04943-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2026. Verfasst von Ming Lei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Hengyang Maternal and Child Health Hospital, Hengyang, 421001, China. Hauptthemen laut MEDLINE: Ferroptosis, Trastuzumab, Organoids, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan Province, Key Project of the Health Commission of Hunan Province, Guiding Plan Project of Hengyang City.
Abstract (Originalsprache)
Trastuzumab is widely used for HER2-positive breast cancer, but its relationship with ferroptosis remains unclear. In this study, patient-derived breast cancer organoids were used to examine trastuzumab-associated ferroptosis-related changes and the possible involvement of p53 signaling. Three independent HER2-positive breast cancer organoid lines were used for the main functional experiments, and three HER2-low organoid lines were included as control models. The IC50-based working concentration of trastuzumab was 66.31 µg/mL. Transcriptome analysis revealed enrichment of ferroptosis- and p53-related pathways after trastuzumab treatment. In HER2-positive organoids, trastuzumab reduced organoid viability and altered organoid morphology, accompanied by increased MDA, Fe²⁺, and ROS levels and decreased GSH/GSSG, SLC7A11, and GPX4 expression. The same treatment did not produce comparable changes in HER2-low organoids. Fer-1 partially attenuated the changes in organoid viability and ferroptosis-related indicators. PFT-α showed a similar partial rescue effect. In addition, p53 knockdown weakened several trastuzumab-associated changes, including alterations in viability, oxidative stress-related markers, and SLC7A11/GPX4 expression. These findings suggest that trastuzumab treatment is associated with ferroptosis-related biochemical and molecular alterations in HER2-positive breast cancer organoids, and that p53-related signaling may participate in this process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, Hengyang Maternal and Child Health Hospital, Hengyang, 421001, China.
- Department of Anesthesiology, Hengyang Maternal and Child Health Hospital, No. 89, Jiefang Road, Yanfeng District, Hengyang, 421001, China.
- Department of science and education, Hengyang Maternal and Child Health Hospital, Hengyang, 421001, China.
- Department of Anesthesiology, Hengyang Maternal and Child Health Hospital, No. 89, Jiefang Road, Yanfeng District, Hengyang, 421001, China. Danny_ho@foxmail.com.
ORCID-Profile: Dan He
Förderung
- Natural Science Foundation of Hunan Province
- Key Project of the Health Commission of Hunan Province
- Guiding Plan Project of Hengyang City
Zitieren
APA
Lei, M., Li, Z., Xiong, C., Xie, F., Liu, L., & He, D. (2026). Trastuzumab treatment is associated with ferroptosis-related alterations in HER2-positive breast cancer organoids. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-026-04943-4
Vancouver
Lei M, Li Z, Xiong C, Xie F, Liu L, He D. Trastuzumab treatment is associated with ferroptosis-related alterations in HER2-positive breast cancer organoids. Cancer Chemotherapy and Pharmacology. 2026. doi:10.1007/s00280-026-04943-4
BibTeX
@article{Lei2026,
author = {Lei, Ming and Li, Zhixiong and Xiong, Chunsong and Xie, Fen and Liu, Lingyan and He, Dan},
title = {Trastuzumab treatment is associated with ferroptosis-related alterations in HER2-positive breast cancer organoids},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
doi = {10.1007/s00280-026-04943-4}
}
EUVIMED